Company search
Overview
Performance
Portfolio
ESG
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Engage
Data as at: 30/04/2024
In
Objective
To achieve a high level of capital growth by investing worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector.
AIC sector
Management group
Frostrow Capital
Company website
Launch date
28/04/1995
March
Domicile
United Kingdom
Fund manager
Sven H. Borho, Trevor M. Polischuk
Dividend frequency
Semi-Annually
Wind-up provisions
Continuation vote at every fifth AGM, the next of which will be in 2024.
| Market Cap (m) | Total assets (m) | Price (last close) | NAV | Discount / premium (%) | Gearing (%) | Dividend yield (%) | Dividend dates | Ongoing charge (%) |
|---|---|---|---|---|---|---|---|---|
| 1,859.30 | 2,054.00 | 343.50 | 379.99 | -9.48 | 1 | 0.90 | Jun, Nov | 0.8 (31/03/2023) |
Scroll
Dividends
Dividends declared in last 12 months
| Ex-Dividend date | Payment date | Dividend amount | Special dividend | Financial year |
|---|---|---|---|---|
| 23/11/2023 | 11/01/2024 | 0.700 | No | 2024 |
| 08/06/2023 | 26/07/2023 | 2.400 | No | 2023 |
Scroll
Performance (%)
| Return type | 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|---|
| Worldwide Healthcare Trust | Share price total return | 7.4 | -7.5 | 38.0 | 194.0 |
| Biotechnology & Healthcare AIC sector | Share price total return | 0.8 | -19.7 | 2.9 | 131.7 |
Scroll
Share structure
Number of shares
541,280,736
60,384,464
Traded volumes (number of shares)
| Yesterday | 1 month | 1 year | 5 years | |
|---|---|---|---|---|
| Total | 1,880,143 | 28,888,503 | 318,974,677 | 1,376,312,737 |
| Average | N/A | 1,465,170 | 1,268,200 | 1,091,610 |
Scroll
Traded values (m)
| Yesterday | 1 month | 1 year | 5 years | |
|---|---|---|---|---|
| Total | 6.46 | 95.90 | 1,003.59 | 4,525.74 |
| Average | N/A | 4.87 | 3.99 | 3.59 |
Scroll
Trading details
Top holdings
Data as at : 31/01/2024
| Investment | % of total assets |
|---|---|
| Eli Lilly and Co | 8.0 |
| Boston Scientific Corp | 6.5 |
| AstraZeneca PLC | 5.9 |
| Intuitive Surgical Inc | 5.8 |
| Novo Nordisk A/S Class B | 5.8 |
| Biogen Inc | 4.6 |
| Merck & Co Inc | 4.1 |
| Daiichi Sankyo Co Ltd | 3.7 |
| Tenet Healthcare Corp | 3.2 |
| Stryker Corp | 3.0 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.
